Vanguard Group Inc. Has $19.77 Million Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Vanguard Group Inc. decreased its holdings in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 22.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,013,558 shares of the company’s stock after selling 592,205 shares during the quarter. Vanguard Group Inc. owned approximately 3.50% of Ginkgo Bioworks worth $19,773,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Forbes J M & Co. LLP grew its holdings in Ginkgo Bioworks by 461.4% in the 4th quarter. Forbes J M & Co. LLP now owns 701,732 shares of the company’s stock valued at $6,891,000 after buying an additional 576,732 shares during the last quarter. SBI Securities Co. Ltd. bought a new position in Ginkgo Bioworks in the fourth quarter worth $29,000. SG Americas Securities LLC acquired a new position in shares of Ginkgo Bioworks in the 4th quarter valued at $199,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Ginkgo Bioworks by 8.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 233,717 shares of the company’s stock worth $2,295,000 after acquiring an additional 17,372 shares during the period. Finally, SPX Gestao de Recursos Ltda bought a new position in shares of Ginkgo Bioworks during the 4th quarter worth about $491,000. Institutional investors and hedge funds own 78.63% of the company’s stock.

Ginkgo Bioworks Trading Down 1.8 %

NYSE DNA opened at $8.10 on Thursday. The stock’s 50 day moving average is $8.57 and its two-hundred day moving average is $9.16. The company has a market capitalization of $470.08 million, a price-to-earnings ratio of -0.62 and a beta of 1.34. Ginkgo Bioworks Holdings, Inc. has a 1-year low of $5.00 and a 1-year high of $45.20.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.